Navigation Links
AMDL CEO Featured in CEOCFO Magazine; Details Progress on DR-70 International Commercialization Strategy & Confidence in FY2009 Financial Forecast
Date:6/17/2009

TUSTIN, Calif., June 17 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its Chairman and CEO Mr. Douglas MacLellan has been featured in CEOCFO Magazine - a daily online investment news publication that delivers market news and analysis to investors through exclusive interviews with venture capital and publicly-traded companies listed on US and International stock exchanges.

In his interview Mr. MacLellan comments on AMDL's continued focus to become a leading pharmaceutical company with three distinct and growing divisions that include In Vitro Diagnostics (IVD), High End Skin Care Products, and China-based Pharmaceuticals; and target goals of achieving profitability across AMDL's US and China-based operations by year end.

Mr. MacLellan also provided updates on AMDL's worldwide commercialization strategy for the Company's DR-70 (FDP) IVD cancer test saying, "We are leveraging last year's US FDA approval for DR-70 with the launch of an international commercialization and have already realized sales revenues in this division. I believe in vitro diagnostics will be a substantial segment for the AMDL -- one that absolutely has the potential to generate equivalent or better returns as compared to our China-based pharmaceutical division."

Since 2006 AMDL has achieved more than 100% in year-over-year gross revenue growth and remains on track with its FY2009 business milestones and financial guidance projections. The Company is featured as the "#1 Small-Cap Stock Pick for 2009" by Flaherty Financial News (www.flahertyfinancialnews.com ), a New York-based investment newsletter, and was named one of the Top 5 fastest growing publicly-traded companies in Orange County by intern
'/>"/>

SOURCE AMDL Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007
4. Allscripts Featured in Microsoft HealthVault Worldwide Launch
5. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
6. Marteks lifesDHA(TM) Featured in New Beech-Nut(R) DHA Plus Baby Food and Cereals
7. Jenny McCarthy Featured at National Autism Conference in Atlanta, November 9
8. Morris Animal Foundation Featured on NASCAR Racecar to Raise Awareness of Pet Cancer
9. Effective Treatment for Fibromyalgia Featured on Oprah Winfrey Show You Dont Have to Live With That Agony!
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Marteks lifesDHA(TM) Featured in Dalco Foods Wellness Line Meat Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... WV (PRWEB) June 19, 2013 The ... individual used the sauna but the overall experience for ... to be positive health-wise. , Mr Mouw, whose Virgina-based ... to the Society’s statement by saying that the type ... learned of a number of counterfeit imitations which frankly, ...
(Date:6/19/2013)... June 19, 2013 Researchers from the ... demonstrated several new studies at ENDO 2013, The ... June 15-18 in San Francisco.     , Mount Sinai researchers ... the role of prostastic acid phosphatase (PAP) in Prostate ... stimulate the thyroid gland; revealed the prevalence of primary ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 CCA ... of Dr. John Baxter to Vice President, Health Services, ... as Director, Mental Health Services for CCA. He ... an honor and great privilege to lead CCA's dedicated ... unique opportunity to serve society and our partners as ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... wellness companies : , In July 2013, Orriant ... optimize their participation rates, and maintain compliance with ... implemented allowing employees to receive wellness incentives if ... Orriant has announced they have been compliant with ...
(Date:6/19/2013)... 2013 Citi Bike has come to New York ... David Perna to know for sure how many patients will choose ... they’ll have the option. In fact, he’s happy about anything ... also make it more convenient for them to visit his office ... of Complimentary Alternative Medicine at Back and Body Medical and an ...
Breaking Medicine News(10 mins):Health News:Health Benefits of Saunas Only Viable with Properly Constructed Models, Warns Manufacturer 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7Health News:CCA Names Dr. John Baxter Vice President, Health Services 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3
... traumatic brain injuries occur, a speedy diagnosis followed by ... and death. A research team, led by Jason D. ... at the U.S. National Institutes of Health, has created ... such as hematomas, which occur when blood vessels become ...
... have been shown to have higher levels of education ... physically active, and have other characteristics that are associated ... been inconsistent in showing that, after adjustment for all ... of cardiovascular disease and mortality than do consumers of ...
... infant survival rates in 19th -Century Montreal in two ... McGill University. Mother,s milk protected vulnerable infants from food ... the arrival of more siblings and that improved the ... Published in the journal Population Studies , ...
... patterns of emergency care for an entire state has ... Indiana over a three-year period were by patients who ... conventional wisdom that patients are tightly bound to health ... The Regenstrief Institute study, "All Health Care Is ...
... Western Reserve University School of Medicine received a $6.75 ... Diabetes and Digestive and Kidney Diseases (NIDDK) to study ... (IBD). For years, scientists have focused their attention on ... in the cause of Crohn,s disease, a chronic debilitating ...
... they,re thought to be more fearful and feel threatened ... Aviv University shows that the anxious may not be hypersensitive ... enough. As part of a study on how the ... a Ph.D. candidate in TAU,s School of Psychological Sciences and ...
Cached Medicine News:Health News:New device for rapid, mobile detection of brain injury 2Health News:Breastfeeding saved babies in 19th- Century Montreal 2Health News:Breastfeeding saved babies in 19th- Century Montreal 3Health News:First study of emergency care for an entire state finds care isn't always local 2Health News:$6.75 million awarded to Case Western Reserve to study IBD 2Health News:Are the anxious oblivious? 2
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: